Chronic Inflammation in Asthma

Tran, Thai; Qiao, Yong‐Kang; You, Huihui; Cheong, Dorothy H.J.

doi:10.1016/b978-0-12-805417-8.00025-1

Cited by 1 publication

(1 citation statement)

References 74 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has an elimination half-life that is less than 1 h and is both a blood schizontocidal as well as a gametocytocidal drug and is the most commonly used ACT due to its rapid parasiticidal and clinical response. Its combination with mefloquine is extremely effective, even against multidrug-resistant P. falciparum, and must be given for a minimum of 3 days [ 76 , 86 , 87 ]. The combination of artemether-lumefantrine, however, is recommended as the first-line therapy of uncomplicated P. falciparum malaria by the WHO.…”

Section: Current Treatment Outlookmentioning

confidence: 99%

Current advances in nanodrug delivery systems for malaria prevention and treatment

Kekani

Witika

2023

Discover Nano

View full text Add to dashboard Cite

Malaria is a life-threatening, blood-borne disease with over two hundred million cases throughout the world and is more prevalent in Sub-Saharan Africa than anywhere else in the world. Over the years, several treatment agents have been developed for malaria; however, most of these active pharmaceutical ingredients exhibit poor aqueous solubility and low bioavailability and may result in drug-resistant parasites, thus increasing malaria cases and eventually, deaths. Factors such as these in therapeutics have led to a better appreciation of nanomaterials. The ability of nanomaterials to function as drug carriers with a high loading capacity and targeted drug delivery, good biocompatibility, and low toxicity renders them an appealing alternative to conventional therapy. Nanomaterials such as dendrimers and liposomes have been demonstrated to be capable of enhancing the efficacy of antimalarial drugs. This review discusses the recent development of nanomaterials and their benefits in drug delivery for the potential treatment of malaria.

show abstract

Section: Current Treatment Outlookmentioning

confidence: 99%